

1

2

Jaagsiekte sheep retrovirus infection induces changes in

3

microRNA expression in the ovine lung

4

5

Maria Contreras Garcia^{a,b}, Anna E. Karagianni^{a,b}, Deepali Vasoya^b,

6

Siddharth Jayaraman^b, Yao-Tang Lin^b, Ann R. Wood^a, Mark P. Dagleish^a,

7

Chris Cousens^a, Mick Watson^b, Finn E. Grey^b, David J. Griffiths^{a#}

8

9

^aMoredun Research Institute, Edinburgh, United Kingdom;

10

^bRoslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh,

11

Edinburgh, United Kingdom

12

13

14

Address correspondence to David J. Griffiths (david.griffiths@moredun.ac.uk)

15

16

Running title: Differentially expressed microRNAs in OPA

17

Keywords: microRNA, JSRV, jaagsiekte, retroviruses, RNA-Seq, lung adenocarcinoma, cancer

18 **ABSTRACT**

19 Ovine pulmonary adenocarcinoma (OPA) is an infectious neoplastic lung disease of sheep
20 caused by jaagsiekte sheep retrovirus. OPA is an important veterinary problem and is also a
21 valuable large animal model for human lung adenocarcinoma. JSRV infects type 2 alveolar
22 epithelial cells in the lung and induces the growth of tumors, but little is known about the
23 molecular events that lead to the activation of oncogenic pathways in infected cells. MicroRNAs
24 (miRNAs) are small RNA molecules of approximately 22 nucleotides with important roles in
25 regulating gene expression in eukaryotes and with well-established roles in cancer. Here we
26 used small-RNA sequencing to investigate the changes in miRNA expression that occur in
27 JSRV-infected ovine lung. After filtering out low abundance miRNAs, we identified expression
28 of 405 miRNAs, 32 of which were differentially expressed in JSRV-infected lung compared to
29 mock-inoculated control lung. Highly upregulated miRNAs included miR-182, miR-183, miR-96
30 and miR-135b, which have also been associated with oncogenic changes in human lung cancer.
31 Network analysis of genes potentially targeted by the deregulated miRNAs identified their
32 involvement in pathways known to be dysregulated in OPA. We found no evidence to support
33 the existence of miRNAs encoded by JSRV. This study provides the first information on miRNA
34 expression in OPA and identifies a number of targets for future studies into the role of these
35 molecules in the pathogenesis of this unique veterinary model for human lung adenocarcinoma.

36

37 **IMPORTANCE**

38 Ovine pulmonary adenocarcinoma is a neoplastic lung disease of sheep caused by jaagsiekte
39 sheep retrovirus (JSRV). OPA is a significant welfare and economic concern for sheep producers
40 and is a valuable large animal model for human lung adenocarcinoma. MicroRNAs are small

41 RNA molecules of approximately 22 nucleotides with important functions in regulating gene
42 expression in eukaryotes and with well-established roles in cancer. In this study, we examined
43 the changes in microRNA expression that occur in the lung in response to JSRV infection. We
44 identified differential expression of a number of host-encoded microRNAs in infected tissue,
45 including microRNAs with roles in human cancer. We found no evidence that JSRV encodes a
46 microRNA. This study provides new insights on the cellular response to JSRV infection in the
47 ovine lung, which will inform future studies into the pathogenesis of OPA in sheep and its use as
48 a model for human lung adenocarcinoma.

49

50

51 **INTRODUCTION**

52 Ovine pulmonary adenocarcinoma (OPA) is a fatal neoplastic lung disease of sheep caused by
53 jaagsiekte sheep retrovirus (JSRV) (1, 2). OPA is present in most sheep-rearing countries and
54 results in significant economic losses for sheep producers. Sheep with clinically overt OPA
55 appear thin, lose condition and are dyspnoeic when exercised. In addition, many affected sheep
56 produce excess fluid which accumulates in the pulmonary airways and may be discharged from
57 the nostrils when the head is lowered, a pathognomonic sign of the disease. OPA is a serious
58 animal welfare issue.

59
60 JSRV infection in sheep induces carcinogenesis of secretory epithelial cells in the distal lung,
61 where proliferating type 2 alveolar epithelial cells (AEC2s) comprise the large majority of tumor
62 cells (3-5). Lesions observed in lungs of clinical cases of OPA resemble those seen in human
63 lepidic pulmonary adenocarcinoma, a rare form of lung cancer previously called
64 bronchioloalveolar carcinoma (6-8). In both malignancies, tumors are typically multifocal and
65 found in the peripheral lung. OPA has therefore been suggested as a suitable model to study
66 early oncogenic events in human lung adenocarcinoma (8, 9).

67
68 JSRV is unusual among oncogenic retroviruses in that its envelope (*env*) gene encodes a
69 dominant oncoprotein that is capable of inducing lung tumors when expressed in sheep and mice
70 (10-12). JSRV Env also induces features of cellular transformation when overexpressed in a
71 variety of cell lines, including morphological changes and activation of protein tyrosine kinase
72 signaling pathways such as PI3K-Akt and Raf-MEK-MAPK (13-16). These pathways are also
73 found to be activated in OPA tumor cells in sheep (17-19) and in JSRV Env-transformed cells in

74 murine models (11, 20). These interesting biological features present OPA as a unique animal
75 model for understanding molecular events in lung carcinogenesis. However, many aspects of the
76 interactions between JSRV and ovine lung tissue have yet to be investigated.

77
78 MicroRNAs (miRNAs) are short, non-coding RNAs of approximately 22 nucleotides that
79 regulate gene expression post-transcriptionally (21). miRNAs were first described in the
80 nematode *Caenorhabditis elegans* (22) and have since been discovered in organisms throughout
81 the plant and animal kingdoms, in viruses and in green algae (23). Many miRNAs exhibit high
82 sequence conservation in related species and some, such as let-7 (24), have homologs in distant
83 species. Binding of miRNAs with their mRNA targets typically occurs by complementarity of
84 the seed sequence (nucleotides 2-8 of the miRNA) to the 3' - untranslated regions of genes (25).
85 The targets of miRNAs may control various biological processes such as developmental timing,
86 cell proliferation, cell death and tissue differentiation (26). Abnormal function of these processes
87 leads to aberrant cell proliferation and many studies have investigated the potential roles of
88 miRNAs in cancer (reviewed in (27, 28)).

89
90 Several viruses encode miRNAs, including herpesviruses, retroviruses and polyomaviruses (29).
91 Virus-encoded miRNAs have been shown to influence cellular pathways related to their
92 replication and pathogenesis. For example, the deltaretrovirus bovine leukemia virus (BLV),
93 encodes 10 mature miRNAs (30). One of these, BLV-miR-B4, has similarity with host miR-29,
94 and is associated with B-cell proliferation and oncogenesis, suggesting that viral miRNAs may
95 play an important role in BLV-mediated transformation. Other retroviruses have been shown to
96 modulate expression of cellular miRNAs in ways that may also influence pathogenesis; for

97 example, mouse mammary tumor virus (MMTV) infection increases expression of members of
98 the oncogenic cluster miR-17-92, which is known to be upregulated in a variety of human
99 cancers, including mammary carcinomas (31). Similarly, human T-cell lymphotropic virus type 1
100 (HTLV-1) infection upregulates miR-93 and miR-130b, which target the pro-apoptotic Tumor
101 Protein 53-Induced Nuclear Protein 1) (32).

102
103 Here, we used small RNA-sequencing to investigate miRNA expression in ovine lung tissue in
104 the early stages of JSRV infection using an experimental lamb infection model. We identified
105 differential expression of a number of miRNAs in infected lung tissue compared to lung tissue
106 from mock-inoculated lambs. The differential expression of the majority of those miRNAs tested
107 was confirmed by RT-qPCR in natural cases of OPA, suggesting an association between OPA
108 and the upregulation of these miRNAs. We found no evidence to support the existence of
109 miRNAs encoded by JSRV. Network analysis of the deregulated miRNAs identified their
110 involvement in pathways previously identified as dysregulated in OPA (33). Collectively, this
111 study provides new information on the host response to JSRV infection that may have relevance
112 for understanding the pathogenesis of OPA and expands the limited knowledge of sheep
113 miRNAs currently available.

114

115 **RESULTS**

116 **Experimentally-induced cases of OPA were used for small RNA-Sequencing.**

117 In order to identify changes in miRNA expression in JSRV-infected lung tissue, we initially
118 examined tissues from experimentally-infected specified pathogen-free (SPF) lambs and age-
119 matched mock-inoculated control lambs. The use of experimentally-infected SPF lambs

120 minimizes the effect of potentially confounding factors such as the presence of other infections
121 or disease stage on miRNA expression. The experimental cases of OPA used have been
122 described previously in studies examining JSRV target cells in the lung (4) and changes in
123 mRNA transcription that occur following JSRV infection (33). Briefly, four 6-day old SPF
124 lambs were experimentally-infected with JSRV, whereas four age-matched control lambs
125 received cell culture medium. Each infected lamb was euthanized when signs of respiratory
126 distress appeared (66 to 85 days post-inoculation) along with an age and sex-matched control
127 lamb. OPA tumor lesions were observed in hematoxylin and eosin-stained lung tissue sections
128 from infected lambs, and this was confirmed by immunohistochemistry (IHC) for the JSRV Env
129 surface (SU) protein (4, 33). Such lesions were not present in lung tissue from mock-inoculated
130 lambs. As is typical for this experimental infection model, the lung tissue of JSRV-infected
131 animals used for RNA extraction was heterogeneous and by histological appearance comprised
132 up to 10% of OPA-affected tissue in a background of normal tissue (4, 33).

133

134 **Detection of differentially expressed miRNAs in JSRV-infected lung tissue.**

135 RNA was extracted from eight discrete sites of the lungs of each animal and pooled for library
136 preparation and sequencing. Small RNA-Seq generated over 19 million reads per sample and,
137 following adapter trimming, over 87% of reads from each sample passed the quality threshold
138 (Table 1). Comparison of the distribution of sequence length of the small RNAs revealed a
139 similar pattern between JSRV-infected and mock-inoculated samples (Fig. 1A). The observed
140 distribution is comparable to that reported in other small RNA-sequencing studies (34-36). The
141 sequencing reads were then aligned to various categories of RNA (Fig. 1B). Over 64% of the
142 total reads from each lamb mapped to miRNAs from miRBase (23), with the majority of the

143 remainder mapping to other classes of RNA. Notably, a small proportion of reads (less than
144 0.003% per sample) mapped to the JSRV genome, raising the possibility that JSRV might
145 encode small RNAs.

146

147 In total, 861 miRNAs were detected across all 8 lambs analyzed (Supplemental Data Set S1). We
148 filtered out 456 miRNAs that were present at low abundance (mean normalized counts across
149 samples lower than 50), as such reads are commonly thought to be unlikely to have biological
150 significance. The remaining 405 miRNAs were used for further analysis. Of these, 318 miRNAs
151 were not listed in the miRBase entry for *Ovis aries*, reflecting the relative paucity of coverage of
152 sheep miRNAs in miRBase. Principal component analysis (PCA) was used to observe the
153 variability among samples and to evaluate the clustering of samples as a first indication of
154 differences between groups. JSRV-infected and mock-inoculated lambs clustered separately in
155 the PCA plot (Fig. 2A) with greater variability within the JSRV-infected group. Notably, one
156 JSRV-infected sample (Infected_F_85_days) was found to cluster more closely with the mock-
157 inoculated group, indicating that the global miRNA expression pattern of this sample was more
158 similar to mock-inoculated lambs. This finding is consistent with our previous analysis of mRNA
159 transcription of the same samples (33), which found a lower level of JSRV infection in this lamb
160 compared to the other lambs in this group.

161

162 Differential expression analysis was then performed to identify miRNAs with an altered
163 expression pattern between JSRV-infected and mock-inoculated lambs. For this analysis we
164 defined differentially expressed miRNAs to be those showing up- or down-regulation following
165 JSRV infection with a false discovery rate (FDR) below 0.05, and a fold-change threshold

166 established at ≤ 0.75 for downregulated miRNAs and ≥ 1.5 for upregulated miRNAs. The
167 decision to establish these fold changes as significant was based on the low percentage of tumor
168 tissue present in the samples to ensure that potential differences were detected while
169 acknowledging the potential for false positives. Using these thresholds, we identified 32
170 miRNAs with significantly altered expression between JSRV-infected and mock-inoculated
171 lambs (Fig. 2B; Table 2; Supplemental Data Set S1). Of these, 26 miRNAs were upregulated in
172 JSRV-infected lambs and 6 were downregulated. As with the PCA, lamb Infected_F_85_days
173 clustered more closely with the mock-inoculated lambs than with the other infected lambs,
174 reflecting the lower level of infection in that animal.

175

176 **Validation of RNA-Seq results by RT-qPCR.**

177 Nine miRNAs were selected for validation of differential expression by RT-qPCR. Seven of
178 these (miR-21-5p, miR-31, miR-96, miR-135b, miR-182, miR-183 and miR-205) were identified
179 based on the following criteria: fold change >1.5 , mean normalized counts >50 , coefficient of
180 variation within groups $<50\%$, FDR <0.01 and a minimum of five independent studies previously
181 reporting their dysregulation or involvement in human lung cancer. In addition, miR-200b-5p
182 and miR-503-5p were included in the validation panel. Although these two miRNAs did not
183 meet the criteria for selection (miR-200b-5p: fold change of 1.46, FDR of 0.016 and mean
184 normalized counts 274.65; miR-503-5p: fold change of 1.56, FDR of 0.0008 and mean
185 normalized counts 11.72), they were of interest due to their known involvement, with validated
186 targets, in lung cancer (37-39). miR-191 was chosen as the endogenous control for RT-qPCR due
187 to its high expression level and low variance among all samples (mean normalized counts >150 ;
188 coefficient of variance $<20\%$) and the lack of any reported involvement in lung cancer or viral

189 infection. The stability of this miRNA was also validated by RT-qPCR and the results showed
190 5.6% coefficient of variance among the eight tested samples (data not shown).

191
192 Initially, we analyzed aliquots of the same RNA samples that had been used for small RNA
193 sequencing. The results confirmed greater abundance of the nine selected miRNAs in the JSRV-
194 infected group compared to the mock-inoculated control group (Fig. 3A, B) ($p < 0.05$). miR-183
195 had the greatest difference in expression between the two groups as it was detected in infected
196 but not in control samples. The RT-qPCR analysis identified high variability within each group
197 of lambs consistent with the results of small RNA-Seq.

198
199 The tissues analyzed in the experimentally-infected lambs represent an early stage of OPA in
200 young animals. In other diseases, the pattern of miRNA expression is known to vary with disease
201 and developmental stage (40-42). Therefore, we next measured the expression of the nine
202 selected miRNAs in lung tissues from adult sheep, including 10 naturally infected OPA cases
203 and 6 clinically healthy sheep (Fig. 3C, D). All of the miRNAs in this panel were detected in
204 both groups, with the exception of miR-183, which was not detected in samples from the
205 clinically healthy control group. In addition, all but one of the miRNAs tested (miR-31) were
206 significantly upregulated ($p < 0.05$) in OPA-affected sheep compared to healthy sheep. These
207 findings indicate that miRNAs identified as upregulated in experimental cases of OPA are also
208 upregulated in natural cases of OPA, increasing confidence that they are involved in the
209 pathogenesis of OPA.

210

211

212 **JSRV does not encode a miRNA.**

213 Small RNA-sequencing reads were mapped to the genome of the JSRV isolate used in the
214 experimental infections (JSRV₂₁; GenBank Accession AF105220.1). The aligned reads were
215 then visualized using Integrative Genomics viewer (IGV 2.3) in order to identify regions to
216 which a disproportionately high number of reads aligned and that might therefore potentially
217 encode viral miRNAs (Fig. 4).

218
219 The most abundant read mapping to JSRV was CCCACGUUGGGCGCCA, which was present in
220 similar numbers in infected (166-329 counts) and uninfected (173-237 counts) animals. This
221 read maps to a site immediately downstream of the JSRV 5'-LTR that is the binding site for a
222 tRNA^{Lys-1,2} molecule that is used to prime reverse transcription (43, 44). Interestingly, this short
223 RNA molecule represents the 3'-terminal 17 nt of the mature tRNA^{Lys-1,2}, suggesting that it is a
224 tRNA fragment (tRF). Recent studies have shown that tRFs are generated by specific cleavage
225 from mature tRNAs and they may have several roles in regulating cellular gene expression (45).

226
227 Apart from the peak of reads representing the tRNA^{Lys-1,2} 3'-tRF, there were only 1-5 additional
228 reads scattered across the genome in mock-inoculated animals. It appears likely that these
229 originate from endogenous retroviruses related to JSRV (enJSRV), which are abundant in the
230 sheep genome and transcribed in many tissues (46). These reads appear to map to JSRV in
231 regions of high sequence similarity to enJSRV. In contrast, in JSRV-infected animals, reads were
232 identified that mapped to several regions of the genome but in most cases at low coverage (Fig.
233 4). However, one exception to this was a region around nt 6400 of the JSRV genome, which
234 accumulated 9-16% of the reads mapping to JSRV (10-49 reads per sample). The greater number

235 of reads mapping to this region of the JSRV genome was not observed in mock-inoculated
236 lambs, confirming that these reads were specific for JSRV-infected animals. The region around
237 nt 6400 of the JSRV genome is part of the *env* gene, which is known to contain splice donor and
238 acceptor sites for the expression of spliced transcripts (47). Potential structural and sequence
239 features that could explain the higher number of reads in this area were investigated; however, no
240 splice acceptors or other motifs were identified that could explain the greater abundance of reads
241 mapping to this region.

242

243 The sequence surrounding nt 6400 of the JSRV genome was then evaluated for evidence that it
244 might encode a miRNA. RNA folding prediction using RNAfold (48) identified the presence of a
245 stem-loop structure of 54 nt in this region (Fig. 5A). Although pre-miRNA stem-loops are
246 usually longer (~ 70 nt), some retroviral miRNAs with shorter stem-loops have been reported
247 (49). Nevertheless, by examining the stem-loop it can be observed that the potential miRNA
248 sequence (UCAUACCAGGCUUCAGCUAAU) is not encoded entirely within the stem of the
249 stem-loop structure, which is a requirement for DICER processing of miRNAs. This suggests
250 that these reads are not derived from a genuine JSRV miRNA. To examine this potential miRNA
251 experimentally, northern blotting was performed on RNA extracted from lung tissue samples
252 from field cases of OPA-affected and clinically healthy sheep, and RNA from 293T cells
253 transfected with plasmids that encode JSRV (pCMV2JS₂₁ and pJSRV₂₁ (43)) (Fig. 5).
254 Hybridization was performed with three labeled probes: two to detect the -5p and -3p versions of
255 the putative miRNA, and one to detect miR-191, which was used as a positive control.

256

257 The northern blot analysis revealed a band approximately 20 nt in size that hybridized with the
258 labelled miR-191 probe (Fig. 5B), confirming successful detection of miR-191 and the integrity
259 of the samples. In addition to the 20 nt band, a band of ~ 70 nt in size was also detected in all
260 samples. This band was observed more clearly after extended exposure of the blot (4-days) and
261 may represent the pre-miRNA mir-191. In contrast, no bands of the expected miRNA size (21 nt)
262 were observed when RNA samples were hybridized with probes for the -5p and -3p versions of
263 the putative JSRV miRNA (Fig. 5B). Hybridization was performed with both -5p and -3p probes
264 because detection of both forms of a miRNA would increase confidence in its existence. Both the
265 -5p and -3p probes hybridized with a band at the top of lanes containing lung RNA from OPA-
266 affected and control sheep, indicating that this sequence was not specific to JSRV-infected
267 tissue. Given that the band was also not present in 293T samples, it is possible that the primer
268 could also be binding to enJSRV sequences. Indeed, a BLASTN search found 18/21 nt identity
269 between the probe and some enJSRV proviruses encoded in the sheep genome. Overall, the
270 result of the northern blotting analysis did not provide any evidence to support the hypothesis
271 that the sequencing reads mapping to the JSRV genome around nt 6400 are miRNAs. The
272 potential origin of these sequencing reads and the reason for their apparent increased abundance
273 remains unknown but may reflect an unidentified genomic feature of JSRV.

274

275 **Prediction and functional enrichment analysis of miRNA target genes.**

276 The small RNA-Seq analysis was performed on the same tissues used previously for mRNA
277 transcriptome analysis (33) and we therefore sought to perform an integrated analysis of the two
278 datasets. In order to identify potential target sites, we first attempted to extract the sequences of
279 3'- untranslated regions of ovine genes from Ensembl. However, only approximately 5500 genes

280 were annotated, which is not sufficient for a robust analysis. As an alternative, we used Ingenuity
281 Pathway Analysis (IPA) software for target gene prediction and functional analysis. IPA
282 identified that there was targeting information available for 30 of the 32 differentially expressed
283 miRNAs (the exceptions were miR-3601 and miR-146b-3p). IPA reported 667 mRNAs related
284 to 267 pathways as targeted by the differentially expressed miRNAs. The results, presented in
285 Supplemental Data Set S2, indicate those mRNA targets that have been experimentally validated
286 and those which are predicted with high or moderate confidence. The main diseases and
287 biofunctions related to these target genes are shown in Fig. 6, which indicates significant
288 enrichment of cancer-related pathways.

289

290 **DISCUSSION**

291 OPA is an important disease of sheep and a unique naturally-occurring model for human lung
292 carcinogenesis. The involvement of miRNAs in cancer led us to investigate miRNA expression
293 in OPA. We identified many miRNAs previously unidentified in sheep and 32 miRNAs that
294 were differentially present in lung tissue from OPA-affected sheep compared to healthy sheep
295 lung. In addition, our analysis found no evidence to support the existence of miRNAs encoded
296 by JSRV.

297

298 405 miRNAs (with mean normalized abundance >50) were found to map to miRNAs in
299 miRBase, of which 87 had been previously reported in sheep and 318 had been reported in other
300 species (cattle, human and goat). There are relatively few annotated miRNAs in sheep due to the
301 limited number of studies that have been performed to date. A study on miRNAs in ovine
302 lentivirus infection (50) also used the approach of mapping RNA sequencing reads to miRBase

303 and also found that most miRNAs mapped to miRNAs of related species, highlighting the known
304 sequence conservation of miRNAs.

305
306 We filtered out miRNAs with a mean number of normalized counts (across all samples) lower
307 than 50, in common with convention, because miRNAs with low counts are unlikely to have
308 biological relevance and tend not to be validated in further RNA-Seq experiments or by RT-
309 qPCR. Of the miRNAs filtered out in this way, when expression is compared between infected
310 and control lambs only 9 had a $P_{adj} < 0.05$. Interestingly, most of these are related to other
311 miRNAs we found to be differentially expressed. For example, miR-135a is related to miR-135b,
312 miR-212 is from the same cluster as miR-132, miR-183-3p is the other arm of miR-183-5p, and
313 miR-106a is from the miR-17 family. In addition, one low-abundance miRNA (miR-503-5p,
314 mean abundance 11.72) was validated as upregulated in OPA by RT-qPCR.

315
316 Similarly, a small proportion of the sequencing reads (between 2 - 5%) did not map to annotated
317 miRNAs or other classes of RNA. While it is possible that some of these unidentified reads may
318 represent novel miRNAs, previous studies have suggested that such reads are typically of low
319 abundance and that their detection in all samples is difficult (51-53). For that reason, we did not
320 investigate those reads further.

321
322 Differential expression analysis of lung tissue samples successfully detected 32 differentially
323 expressed miRNAs in JSRV-infected lambs compared to mock-inoculated controls. Of those
324 miRNAs, only six were found to be downregulated with the remainder being upregulated in
325 infected animals. While studies on miRNA dysregulation in cancer typically report a global

326 downregulation of miRNAs in diseased tissue (54), the small number of specific downregulated
327 miRNAs found here is most likely explained by the nature of the tissue samples used. Lung
328 tissue samples from JSRV-infected lambs comprise small foci of tumor cells with the majority of
329 the sample tissue, as much as 90%, being histologically normal. The high proportion of
330 histologically normal tissue might therefore dilute the signal from downregulated miRNAs,
331 rendering them undetectable in our analysis (55, 56). Such samples therefore also have greater
332 sensitivity to detect upregulated miRNAs than downregulated miRNAs.

333

334 The heterogeneous nature of the tissue used for small RNA-Seq might also underlie some of the
335 variability in miRNA expression in the JSRV-infected samples, as not all tissue samples will
336 have the same proportion of tumor cells. Furthermore, in addition to tumor cells, lung tissue has
337 many cell types, each of which might change in relative abundance within the affected tissue,
338 and each of which might change their expression phenotype in the presence of JSRV-infected
339 cells. Despite these complexities, the whole tissue approach provides a snapshot of global
340 changes in miRNA expression in OPA-affected lung, and provides a starting point for the
341 identification of cell type-specific changes using enriched or purified cell populations.

342

343 The target genes of the differentially expressed miRNAs have not been investigated in sheep, but
344 some potential targets have been identified in humans. It may be difficult to extrapolate between
345 human and sheep studies due to differences in gene sequences and in regulatory networks
346 between the two species; however, given the transcriptional similarities between OPA and
347 human non-small cell lung cancer (NSCLC) (33), comparison with human cancer studies can
348 give clues to the roles of specific miRNAs. For example, miR-183, miR-182 and miR-96 were

349 the most upregulated miRNAs in JSRV-infected lung tissue. In humans, these three miRNAs
350 form a cluster, encoded on chromosome 7. In normal tissues, miR-183-182-96 cluster members
351 have well-established roles in the development of sensory organs including the eye and ear (57,
352 58) and typically show low expression levels in other healthy tissues. However, these miRNAs
353 consistently show increased expression in cancer and they are regarded as oncomiRs that are
354 positively associated with cancer progression in a number of cancer types (59, 60). In human
355 NSCLC, miR-183 has been reported to act to both promote and to restrict tumorigenesis (60-63).

356

357 In contrast to the established role of the miR-183-182-96 cluster in cancer, few studies have
358 demonstrated its activation during infection, although roles have been reported in clonal
359 expansion of helper T lymphocytes (64), suppression of natural killer cell function (65) and
360 positive regulation of interferon responses (66). Notably, miR-183 is upregulated in tumors
361 generated by infection with MMTV, another member of the betaretrovirus genus (31). Whether
362 this is a result of the transformation process or the response to infection is unclear.

363

364 The miRNAs upregulated in OPA have targets in oncogenic pathways known to be activated in
365 OPA. For example, the JSRV Env protein activates the PI3K-Akt-mTor signaling pathway (11,
366 13, 18, 67, 68) and miR-21 (69, 70), miR-183 (60) and miR-205 (71-73) all target *PTEN* and/or
367 *PPP2CB* phosphatases, which negatively regulate this pathway. In addition, miR-31 targets
368 *RASA1* and *SPRED1* in the MAPK pathway (74). Finally, miR-135b is known to regulate several
369 factors involved in Hippo pathway signaling, including LATS2, NDR2, MOB1b and β -TrCP
370 (75). Hippo signaling is crucial for alveolargenesis and dysregulation of this pathway has been
371 described previously in OPA (33) and in human NSCLC (76). Collectively, the miRNAs found

372 to be most differentially expressed in OPA are consistent with those that would be predicted
373 based on previous work on human cancer and in murine models.

374

375 The enrichment analysis of the predicted target genes of the differentially expressed miRNAs
376 was performed using IPA. This analysis revealed cancer-related functions to be highly enriched
377 in the miRNA:mRNA data sets (Fig. 6; Supplemental Data S2). The IPA miRNA target gene
378 analysis uses information from predicted targets of mammalian miRNAs, based on the
379 observation that the majority of mammalian mRNAs are conserved targets of miRNAs (77-79).
380 A similar analysis was reported previously with a dataset from cattle (80). Indeed, the
381 evolvability of microRNA target sites among mammals (*i.e.*, the ‘proportion of evolutionarily
382 changeable targets’) is estimated to be as low as 20% (79). However, as miRNA target sites are
383 relatively uncharacterized in sheep, despite these results being consistent with previous studies
384 on human lung cancer and OPA, further experimental validation is required to confirm the
385 interactions.

386

387 Previous studies have identified miRNAs in other retroviruses, including BLV, HIV-1 and
388 bovine and simian spumaretroviruses (30, 49, 81, 82). The small RNA-Seq data obtained in this
389 study indicated increased abundance of reads mapping to a short region within the JSRV *env*
390 gene, suggesting the possibility that JSRV might encode a miRNA. However, this was not
391 supported by experimental analysis of sheep tissue or cell culture samples (Fig. 5), and we
392 conclude that JSRV does not, in fact, encode a miRNA. This is consistent with small RNA-Seq
393 studies of other betaretroviruses, including MMTV (31) and enzootic nasal tumor virus (83) and
394 a bioinformatics screen of all retroviral genome sequences (30).

395

396 Although our primary focus in this study was to characterize miRNA expression in OPA, we also
397 identified the presence of a 3' -tRF derived from tRNA^{Lys-1,2} in sheep lung samples due to the
398 presence of the complementary sequence in the primer binding site (PBS) region of the JSRV
399 genome (43). A similar finding has been reported in an MMTV-infected mammary cell line (31).
400 The potential for 3' -tRFs to bind retroviral and retrotransposon genomes at the PBS is well
401 established; for example, tRFs are able to repress expression of retrotransposons with a cognate
402 PBS in preimplantation stem cells (84). It can be speculated that the tRF of tRNA^{Lys-1,2} could
403 perhaps inhibit the replication of JSRV; for example, by competing for binding of the PBS with
404 the mature full length tRNA. Similarly, this tRF might act to inhibit retrotransposition of
405 enJSRV. However, it is unclear whether the tRF is sufficiently abundant in infected cells to exert
406 such an effect. Further studies are necessary to directly address these questions. Notably, this tRF
407 was present at a similar abundance in lung tissue from mock-inoculated and JSRV-infected
408 lambs, suggesting that its generation was not stimulated by JSRV infection.

409

410 In summary, this study is the first to examine miRNA expression in OPA and has identified the
411 differential expression of several miRNAs in affected lung tissue. These findings are a first step
412 towards understanding the role of miRNAs and their predicted gene targets in OPA, which could
413 be potentially exploited as biomarkers of the disease or as a tool to investigate the transformation
414 process. In addition, this study contributes towards further characterization of host gene
415 expression in OPA, which could aid the exploration of OPA as a human lung cancer model.

416

417

418 MATERIALS AND METHODS

419 *In vivo studies.*

420 Samples used for RNA-Seq were available from a previous study in which SPF lambs were
421 either experimentally-infected with JSRV₂₁ (n=4) or mock-inoculated with culture supernatant
422 (n=4) by intra-tracheal injection as described previously (4, 33). Lambs were born and housed
423 under SPF conditions and were killed humanely by intravenous injection of sodium pentobarbital
424 at the first clinical signs of respiratory distress. Age-matched controls were killed humanely at
425 the same time. Post-mortem, tissue sections were collected from 24 different locations in the
426 lungs, snap frozen in liquid nitrogen and stored at -80°C until analysis. Clinically healthy female
427 adult sheep (n=6) and female OPA-affected adult sheep (n=10) were donated from local farms.
428 Tissues from the lungs were collected at necropsy and stored at -80°C in the same way as
429 samples from experimental cases. All procedures involving animals were performed with
430 approval from the Moredun Research Institute Animal Welfare and Ethical Review Body and in
431 conformance with the UK Animals (Scientific Procedures) Act 1986.

432

433 **RNA extraction.** Lung tissue samples collected post-mortem and stored at -80°C were used to
434 obtain RNA. From each experimental case, tissue sections from 8 different locations in the lungs
435 were cut using a cryostat to represent the global state of the lung. Three 15 µm cryosections from
436 each lung sample were collected in FastPrep lysing matrix D tubes (MP Biomedicals) and
437 homogenized with a Precellys Evolution Tissue Homogenizer. RNA extraction was performed
438 using the RNeasy Plus Micro procedure (Qiagen), according to the manufacturer's protocol for
439 isolation of total RNA including small RNAs. Samples derived from the same animal were
440 pooled together and used for small-RNA sequencing. The quality and integrity of RNA samples

441 was assessed using Nanodrop ONE and Agilent Bioanalyser (Agilent 2100) and only samples
442 with RIN > 6.0, and 260/280 ratio > 1.9 were submitted for small-RNA sequencing.

443

444 **RNA sequencing and bioinformatics analysis.**

445 RNA-Seq was performed by Edinburgh Genomics (<https://genomics.ed.ac.uk/>). Library
446 preparation was performed using a TruSeq Small RNA Sample Preparation kit (11 PCR cycles)
447 and size selection of libraries was performed using Blue Pippin (Sage Science) selecting
448 products of 120-163 bp. Libraries were quality checked by HS Qubit (Thermo) and Bioanalyzer
449 (Agilent), before sequencing in a single lane of an Illumina HiSeq2500 (v4 High Output, 50-base
450 single-end sequencing).

451

452 The quality of raw sequencing data was assessed, low quality reads were removed (Phred score <
453 28) and adapters were trimmed using Cutadapt (85). To select the optimum miRNA size,
454 trimmed reads longer than 28 nt and shorter than 17 nt were filtered out. The selected reads were
455 then mapped to ovine, bovine, human and caprine miRNA sequences of miRBase v.22.1 (23)
456 using NovoAlign (Novocraft Technologies) with parameters: -m, -s 1, -t 30, -h 60. miRBase
457 miRNA entries with identical sequences but different species of origin were grouped together in
458 a single entry and the species prefix removed. In some instances, reads mapped to homolog
459 miRNAs from different species which did not have an identical sequence. This mapping to
460 highly similar but non-identical sequences is due to the presence of isomiRs, which are miRNA
461 isoforms that originate from the same miRNA gene (21). In those instances, reads were not
462 merged into a single entry. miRNA nomenclature was maintained so that it would reflect the

463 miRBase entry name without the species prefix. The -3p and -5p suffixes were kept where
464 present.

465

466 Bam files were then analyzed, and raw reads were normalized in MATLAB (MathWorks) based
467 on size factors. This normalization approach consists of considering a size factor for each library
468 to compute the effective library size. The size factors are calculated by taking the median of the
469 ratios of observed counts to those of a reference sample, whose counts are determined by
470 calculating the mean of each gene across all samples (86). By dividing the counts of each library
471 by the corresponding size factors, all counts are in the same scale, making them comparable. A
472 threshold was then established to remove reads with low numbers of normalized counts from the
473 differential expression analysis. An average of 50 normalized counts across samples was
474 established as a cut-off, based on published literature (87-90).

475

476 Differential expression analysis and statistics were also performed in MATLAB using the
477 negative binomial model (nbintest) with the 'Constant' option. A threshold FDR < 0.05 was
478 established as statistically significant. Data used for PCA plots consisted of normalized counts of
479 all miRNAs above the established threshold of an average of 50 normalized counts. PCA plots
480 were created using RStudio, using the pam function of ggplot2 (ggfortify) (91). Data used for
481 heatmaps consisted of the differentially expressed miRNAs. Heatmaps were created using
482 RStudio, using the pheatmap function. Default options of the pheatmap function were used, with
483 the following exceptions: scale was set to "row", column clustering distance was "correlation",
484 row clustering distance was "Euclidean", clustering method was "average".

485

486 Reads were also mapped to JSRV₂₁ (GenBank accession AF105220.1) and enJSRV
487 (EF680301.1). Reads were counted using a custom-made Perl Script that allowed only 1
488 mismatch. Alignments were visualized using Integrative Genomics Viewer (Broad Institute;
489 <https://software.broadinstitute.org/software/igv/>).

490

491 **Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for detection of**
492 **miRNAs.**

493 The expression of miRNAs was assessed using RT-qPCR with the TaqMan Advanced miRNA
494 cDNA Synthesis Kit (Applied Biosystems) in conjunction with Taqman Advanced miRNA
495 assays (Applied Biosystems, assays: hsa-miR-135b-5p, hsa-miR-182-5p, hsa-miR-183-5p, hsa-
496 miR-200b-5p, hsa-miR-205-5p, rno-miR-21-5p, hsa-miR-31-5p, mmu-miR-503-5p, hsa-miR-96-
497 5p, hsa-miR-191-5p). 10 ng of RNA were used per reaction. In brief, the protocol requires a
498 poly-A tailing reaction and a ligation reaction to be performed before reverse transcription,
499 allowing universal primers to be used in the reverse transcription reaction. A universal
500 amplification reaction followed the reverse transcription, which increased the starting cDNA
501 input for qPCR. All these reactions were performed according to manufacturer's instructions
502 using a Biometra T-one thermocycler (Analytik Jena). Quantitative PCRs (qPCRs) were
503 performed using the Taqman universal PCR mastermix (Applied Biosystems) as instructed in the
504 manufacturer's protocol and each of the sample-target combinations were assayed in duplicate.
505 qPCR reactions were run in the ABI 7500 Real time PCR system (Applied Biosystems) with
506 cycling conditions: 2 minutes at 50°C, 10 minutes at 95°C, and 40 cycles at 95°C for 15 seconds
507 followed by 1 minute at 60°C.

508

509 **Validation of RT-qPCR parameters.**

510 Efficiency (E) of qPCR was assessed by making six serial 5-fold dilutions of the template in
511 molecular grade water and performing the qPCR reaction in duplicate for each dilution.
512 Efficiency was then calculated by plotting the Ct values of each reaction against the logarithm of
513 the template concentration and fitting a line through the points in the plot. The slope of the fitted
514 line was used to calculate the efficiency percentage using the following equation: $E = (10^{-1/\text{slope}}) - 1$.
515 The calculated efficiencies ranged from 92.35% to 107.71%.

516

517 **RNA-structure analysis.**

518 Prediction of the stem-loop structure in the putative miRNA encoded in the region of nt 6400 of
519 the JSRV genome was performed using RNAfold (48) ([http://rna.tbi.univie.ac.at/cgi-](http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi)
520 [bin/RNAWebSuite/RNAfold.cgi](http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi)).

521

522 **Northern blotting.**

523 RNA samples for northern blotting were concentrated by ethanol precipitation to achieve
524 concentrations greater than 800 ng/ μ l. Northern blotting was performed as previously described
525 (92). Briefly, electrophoresis was performed with a 15% acrylamide gel and gels were stained
526 with ethidium bromide and analyzed under ultraviolet light to visualize tRNAs and assess sample
527 degradation. RNA was transferred to Amersham Hybond-N+ membranes (GE Healthcare) with a
528 mini-Protean blotting system (Biorad) in 0.5 \times Tris Borate buffer for 45 minutes at 30 V,
529 followed by 15 minutes at 35 V and 15 minutes at 40 V. The marker bands corresponding to 70
530 nt (tRNAs), 30 nt (band produced by xylene cyanol) and 10 nt (band produced by bromophenol
531 blue) were marked with pencil in the membranes as size indicators. Crosslinking of the RNA to

532 the membranes was performed with a UV Stratalinker 1800 (Stratagene) at 1200 $\mu\text{J}/\text{m}^2$.
533 Membranes were left to dry overnight at room temperature.
534
535 $[\gamma\text{-}^{32}\text{P}]\text{dATP}$ -radiolabeled oligonucleotide probes were prepared by mixing 1 μl of 10 pmol
536 oligonucleotide, 1 μl 10 \times T4 polynucleotide kinase (PNK) buffer (NEB), 6 μl of water, 1 μl T4
537 PNK (NEB) and 1 μl ATP $[\gamma\text{-}^{32}\text{P}]$ 250 μCi (Perkin Elmer) and incubating at 37°C for 1 h. The
538 probes used were: JS-5p candidate JSRV miRNA TCATACCAGGCTTCAGCTATT, JS-3p
539 candidate JSRV miRNA AATAATTCTAAAGCAGTTTCA, and miR-191/oar-miR-191/hsa-
540 miR191 AGCTGCTTTTGGGATTCCGTTG. The labelled probes were then diluted in 40 μl of
541 water and separated from free $[\gamma\text{-}^{32}\text{P}]\text{dATP}$ by gel filtration (Illustra Microspin columns; GE
542 Healthcare). Dried membranes were pre-hybridized in 8 ml of pre-warmed ExpressHyb buffer
543 (Clontech) for 1 h at 55°C before adding filtered ^{32}P -labeled probes and incubating at 38.5°C
544 overnight (Biometra OV5; Analytik Jena). The membranes were then washed with 40 ml pre-
545 warmed washing buffer (2 \times SSC (20 \times SSC stock: 175.3 g/l sodium chloride and 88.2 g/l
546 sodium citrate in water), 0.1% SDS (Sigma Aldrich) in water). Four washes were performed (20
547 mins each; 38.5°C) after which membranes were put in contact with filter paper, pre-soaked in 2
548 \times SSC, and heat-sealed in Seal-o-meal. Labelled bands were then exposed to Biomax MR film
549 (Carestream) inside a Biomax MS screen (Carestream) at -80°C for four days. The film was
550 developed with an SRX-101A film processor (Konica Minolta).

551
552 **Analysis of differentially expressed miRNA and mRNA targets and functional assessment.**

553 The miRNA target genes were obtained using the MicroRNA Target Filter tool of Qiagen's
554 Ingenuity Pathway Analysis (IPA), as described previously (80, 93). The analysis is based on

555 four target prediction databases TargetScan, miRecords, Ingenuity Expert Findings and TarBase.
556 Only the target genes that were present in the differentially expressed dataset published
557 previously (33) were included in the analysis. Both mRNA-Seq and miRNA-Seq data derive
558 from the same tissue samples. A threshold was applied such that only negatively correlated
559 miRNA:mRNA pairs were included in the analysis. The functional enrichment of miRNA -
560 mRNA target was also performed using IPA software to identify enriched canonical pathways
561 and biological processes related to this dataset.

562

563 **Data availability**

564 The raw RNA-Seq reads (fastq data) of each sample are present in the European Nucleotide
565 Archive with the accession number PRJEB47862.

566

567 **ACKNOWLEDGEMENTS**

568 We thank Edinburgh Genomics (<https://genomics.ed.ac.uk/>) for conducting the RNA-Seq
569 experiments and Jeanie Finlayson for excellent technical assistance. We thank the staff of the
570 Moredun Research Institute Bioservices Division for exceptional animal care and the farmers
571 who support our work through the donation of OPA-affected sheep. This project was supported
572 by the Moredun Foundation, the Scottish Government Rural and Environment Science and
573 Analytical Services Division (RESAS) and the Biotechnology and Biological Sciences Research
574 Council (grants BB/L009129/1 and BB/L008505/1), including the Institute Strategic Program,
575 and national capability awards to The Roslin Institute (grants BB/P013740/1, BB/P013759/1,
576 BB/P013732/1, BB/J004235/1, BB/J004243/1, BBS/E/D/20002173, and BBS/E/D/20002174).

577

578 **REFERENCES**

- 579 1. Fan H. 2003. Jaagsiekte Sheep Retrovirus and Lung Cancer. Springer Berlin Heidelberg.
- 580 2. Griffiths DJ, Martineau HM, Cousens C. 2010. Pathology and pathogenesis of ovine
581 pulmonary adenocarcinoma. *J Comp Pathol* 142:260-83.
- 582 3. De las Heras M, de Martino A, Borobia M, Ortin A, Alvarez R, Borderias L, Gimenez-Más
583 J. 2014. Solitary tumours associated with Jaagsiekte retrovirus in sheep are heterogeneous
584 and contain cells expressing markers identifying progenitor cells in lung repair. *J Comp*
585 *Pathol* 150:138-147.
- 586 4. Martineau HM, Cousens C, Imlach S, Dagleish MP, Griffiths DJ. 2011. Jaagsiekte sheep
587 retrovirus infects multiple cell types in the ovine lung. *J Virol* 85:3341-55.
- 588 5. Murgia C, Caporale M, Ceesay O, Di Francesco G, Ferri N, Varasano V, de las Heras M,
589 Palmarini M. 2011. Lung adenocarcinoma originates from retrovirus infection of
590 proliferating type 2 pneumocytes during pulmonary post-natal development or tissue repair.
591 *PLoS Pathog* 7:e1002014.
- 592 6. Palmarini M, Fan H. 2001. Retrovirus-induced ovine pulmonary adenocarcinoma, an animal
593 model for lung cancer. *J Natl Cancer Inst* 93:1603-1614.
- 594 7. Perk K, Hod I. 1982. Sheep lung carcinoma: an endemic analogue of a sporadic human
595 neoplasm. *J Natl Cancer Inst* 69:747-9.
- 596 8. Youssef G, Wallace WA, Dagleish MP, Cousens C, Griffiths DJ. 2015. Ovine pulmonary
597 adenocarcinoma: a large animal model for human lung cancer. *ILAR J* 56:99-115.
- 598 9. Mornex JF, Thivolet F, De las Heras M, Leroux C. 2003. Pathology of human
599 bronchioloalveolar carcinoma and its relationship to the ovine disease. *Curr Top Microbiol*
600 *Immunol* 275:225-48.

- 601 10. Caporale M, Cousens C, Centorame P, Pinoni C, De las Heras M, Palmarini M. 2006.
602 Expression of the jaagsiekte sheep retrovirus envelope glycoprotein is sufficient to induce
603 lung tumors in sheep. *J Virol* 80:8030-7.
- 604 11. Linnerth-Petrik NM, Santry LA, Yu DL, Wootton SK. 2012. Adeno-associated virus vector
605 mediated expression of an oncogenic retroviral envelope protein induces lung
606 adenocarcinomas in immunocompetent mice. *PLoS One* 7:e51400.
- 607 12. Wootton SK, Halbert CL, Miller AD. 2005. Sheep retrovirus structural protein induces lung
608 tumours. *Nature* 434:904.
- 609 13. Maeda N, Fu W, Ortin A, de las Heras M, Fan H. 2005. Roles of the Ras-MEK-mitogen-
610 activated protein kinase and phosphatidylinositol 3-kinase-Akt-mTOR pathways in
611 Jaagsiekte sheep retrovirus-induced transformation of rodent fibroblast and epithelial cell
612 lines. *J Virol* 79:4440-50.
- 613 14. Maeda N, Palmarini M, Murgia C, Fan H. 2001. Direct transformation of rodent fibroblasts
614 by jaagsiekte sheep retrovirus DNA. *Proc Natl Acad Sci U S A* 98:4449-54.
- 615 15. Rai SK, Duh FM, Vigdorovich V, Danilkovitch-Miagkova A, Lerman MI, Miller AD. 2001.
616 Candidate tumor suppressor HYAL2 is a glycosylphosphatidylinositol (GPI)-anchored cell-
617 surface receptor for jaagsiekte sheep retrovirus, the envelope protein of which mediates
618 oncogenic transformation. *Proc Natl Acad Sci U S A* 98:4443-8.
- 619 16. Zavala G, Pretto C, Chow YH, Jones L, Alberti A, Grego E, De las Heras M, Palmarini M.
620 2003. Relevance of Akt phosphorylation in cell transformation induced by Jaagsiekte sheep
621 retrovirus. *Virology* 312:95-105.

- 622 17. Archer F, Jacquier E, Lyon M, Chastang J, Cottin V, Mornex JF, Leroux C. 2007. Alveolar
623 type II cells isolated from pulmonary adenocarcinoma: a model for JSRV expression in
624 vitro. *Am J Respir Cell Mol Biol* 36:534-40.
- 625 18. Cousens C, Alleaume C, Bijsmans E, Martineau HM, Finlayson J, Dagleish MP, Griffiths
626 DJ. 2015. Jaagsiekte sheep retrovirus infection of lung slice cultures. *Retrovirology* 12:31.
- 627 19. De Las Heras M, Ortin A, Benito A, Summers C, Ferrer LM, Sharp JM. 2006. In-situ
628 demonstration of mitogen-activated protein kinase Erk 1/2 signalling pathway in contagious
629 respiratory tumours of sheep and goats. *J Comp Pathol* 135:1-10.
- 630 20. Linnerth-Petrik NM, Walsh SR, Bogner PN, Morrison C, Wootton SK. 2014. Jaagsiekte
631 sheep retrovirus detected in human lung cancer tissue arrays. *BMC Res Notes* 7:160.
- 632 21. Bartel DP. 2018. Metazoan MicroRNAs. *Cell* 173:20-51.
- 633 22. Lee RC, Feinbaum RL, Ambros V. 1993. The *C. elegans* heterochronic gene *lin-4* encodes
634 small RNAs with antisense complementarity to *lin-14*. *Cell* 75:843-54.
- 635 23. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. 2008. miRBase: tools for
636 microRNA genomics. *Nuc Acids Res* 36:D154-8.
- 637 24. Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller B, Hayward DC,
638 Ball EE, Degnan B, Muller P, Spring J, Srinivasan A, Fishman M, Finnerty J, Corbo J,
639 Levine M, Leahy P, Davidson E, Ruvkun G. 2000. Conservation of the sequence and
640 temporal expression of *let-7* heterochronic regulatory RNA. *Nature* 408:86-9.
- 641 25. Bartel DP. 2009. MicroRNAs: target recognition and regulatory functions. *Cell* 136:215-33.
- 642 26. Pichler M, Calin GA. 2015. MicroRNAs in cancer: from developmental genes in worms to
643 their clinical application in patients. *Br J Cancer* 113:569-73.
- 644 27. Lee YS, Dutta A. 2009. MicroRNAs in cancer. *Annu Rev Pathol* 4:199-227.

- 645 28. Lin PY, Yu SL, Yang PC. 2010. MicroRNA in lung cancer. *Br J Cancer* 103:1144-8.
- 646 29. Kincaid RP, Sullivan CS. 2012. Virus-encoded microRNAs: an overview and a look to the
647 future. *PLoS Pathog* 8:e1003018.
- 648 30. Kincaid RP, Burke JM, Sullivan CS. 2012. RNA virus microRNA that mimics a B-cell
649 oncomiR. *Proc Natl Acad Sci U S A* 109:3077-82.
- 650 31. Kincaid RP, Panicker NG, Lozano MM, Sullivan CS, Dudley JP, Mustafa F. 2018. MMTV
651 does not encode viral microRNAs but alters the levels of cancer-associated host
652 microRNAs. *Virology* 513:180-187.
- 653 32. Yeung ML, Yasunaga J, Bennasser Y, Dusetti N, Harris D, Ahmad N, Matsuoka M, Jeang
654 KT. 2008. Roles for microRNAs, miR-93 and miR-130b, and tumor protein 53-induced
655 nuclear protein 1 tumor suppressor in cell growth dysregulation by human T-cell
656 lymphotropic virus 1. *Cancer Res* 68:8976-85.
- 657 33. Karagianni AE, Vasoya D, Finlayson J, Martineau HM, Wood AR, Cousens C, Dagleish
658 MP, Watson M, Griffiths DJ. 2019. Transcriptional Response of Ovine Lung to Infection
659 with Jaagsiekte Sheep Retrovirus. *J Virol* 93.
- 660 34. Chen F, Xu XY, Zhang M, Chen C, Shao HT, Shi Y. 2019. Deep sequencing profiles
661 MicroRNAs related to *Aspergillus fumigatus* infection in lung tissues of mice. *Journal of*
662 *Microbiology, Immunol Infect* 52:90-99.
- 663 35. Li N, You X, Chen T, Mackowiak SD, Friedlander MR, Weigt M, Du H, Gogol-Doring A,
664 Chang Z, Dieterich C, Hu Y, Chen W. 2013. Global profiling of miRNAs and the hairpin
665 precursors: insights into miRNA processing and novel miRNA discovery. *Nuc Acids Res*
666 41:3619-34.

- 667 36. Peng X, Gralinski L, Ferris MT, Frieman MB, Thomas MJ, Proll S, Korth MJ, Tisoncik JR,
668 Heise M, Luo S. 2011. Integrative deep sequencing of the mouse lung transcriptome reveals
669 differential expression of diverse classes of small RNAs in response to respiratory virus
670 infection. *mBio* 2:e00198-11.
- 671 37. Pacurari M, Addison JB, Bondalapati N, Wan YW, Luo D, Qian Y, Castranova V, Ivanov
672 AV, Guo NL. 2013. The microRNA-200 family targets multiple non-small cell lung cancer
673 prognostic markers in H1299 cells and BEAS-2B cells. *Int J Oncol* 43:548-60.
- 674 38. Chen D-Q, Pan B-Z, Huang J-Y, Zhang K, Cui S-Y, De W, Wang R, Chen L-B. 2014.
675 HDAC 1/4-mediated silencing of microRNA-200b promotes chemoresistance in human lung
676 adenocarcinoma cells. *Oncotarget* 5:3333.
- 677 39. Yang Y, Liu L, Zhang Y, Guan H, Wu J, Zhu X, Yuan J, Li M. 2014. MiR-503 targets PI3K
678 p85 and IKK-beta and suppresses progression of non-small cell lung cancer. *Int J Cancer*
679 135:1531-42.
- 680 40. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A,
681 Kamphorst AO, Landthaler M, Lin C, Socci ND, Hermida L, Fulci V, Chiaretti S, Foa R,
682 Schliwka J, Fuchs U, Novosel A, Muller RU, Schermer B, Bissels U, Inman J, Phan Q,
683 Chien M, Weir DB, Choksi R, De Vita G, Frezzetti D, Trompeter HI, Hornung V, Teng G,
684 Hartmann G, Palkovits M, Di Lauro R, Wernet P, Macino G, Rogler CE, Nagle JW, Ju J,
685 Papavasiliou FN, Benzing T, Lichter P, Tam W, Brownstein MJ, Bosio A, Borkhardt A,
686 Russo JJ, Sander C, Zavolan M, et al. 2007. A mammalian microRNA expression atlas
687 based on small RNA library sequencing. *Cell* 129:1401-14.

- 688 41. Mancuso R, Hernis A, Agostini S, Rovaris M, Caputo D, Clerici M. 2015. MicroRNA-572
689 expression in multiple sclerosis patients with different patterns of clinical progression. *J*
690 *Transl Med* 13:148.
- 691 42. Zheng W, Zhao J, Tao Y, Guo M, Ya Z, Chen C, Qin N, Zheng J, Luo J, Xu L. 2018.
692 MicroRNA-21: A promising biomarker for the prognosis and diagnosis of non-small cell
693 lung cancer. *Oncol Lett* 16:2777-2782.
- 694 43. Palmarini M, Sharp JM, de las Heras M, Fan H. 1999. Jaagsiekte sheep retrovirus is
695 necessary and sufficient to induce a contagious lung cancer in sheep. *J Virol* 73:6964-72.
- 696 44. York D, Vigne R, Verwoerd D, Querat G. 1992. Nucleotide sequence of the jaagsiekte
697 retrovirus, an exogenous and endogenous type D and B retrovirus of sheep and goats. *J Virol*
698 66:4930-4939.
- 699 45. Magee R, Rigoutsos I. 2020. On the expanding roles of tRNA fragments in modulating cell
700 behavior. *Nuc Acids Res* 48:9433-9448.
- 701 46. Palmarini M, Mura M, Spencer TE. 2004. Endogenous betaretroviruses of sheep: teaching
702 new lessons in retroviral interference and adaptation. *J Gen Virol* 85:1-13.
- 703 47. Nitta T, Hofacre A, Hull S, Fan H. 2009. Identification and mutational analysis of a Rej
704 response element in Jaagsiekte sheep retrovirus RNA. *J Virol* 83:12499-511.
- 705 48. Langdon WB, Petke J, Lorenz R. 2018. Evolving better RNAfold structure prediction.
706 *Lecture Notes in Computer Science*, 10781: 220-236.
- 707 49. Kincaid RP, Chen Y, Cox JE, Rethwilm A, Sullivan CS. 2014. Noncanonical microRNA
708 (miRNA) biogenesis gives rise to retroviral mimics of lymphoproliferative and
709 immunosuppressive host miRNAs. *mBio* 5:e00074-14.

- 710 50. Bilbao-Arribas M, Abendaño N, Varela-Martínez E, Reina R, de Andrés D, Jugo BM. 2019.
711 Expression analysis of lung miRNAs responding to ovine VM virus infection by RNA-seq.
712 BMC Genomics 20:62-62.
- 713 51. Farrell D, Shaughnessy RG, Britton L, MacHugh DE, Markey B, Gordon SV. 2015. The
714 Identification of Circulating MiRNA in Bovine Serum and Their Potential as Novel
715 Biomarkers of Early Mycobacterium avium subsp paratuberculosis Infection. PLoS One
716 10:e0134310.
- 717 52. Meng F, Hackenberg M, Li Z, Yan J, Chen T. 2012. Discovery of novel microRNAs in rat
718 kidney using next generation sequencing and microarray validation. PLoS One 7:e34394.
- 719 53. Wake C, Labadorf A, Dumitriu A, Hoss AG, Bregu J, Albrecht KH, DeStefano AL, Myers
720 RH. 2016. Novel microRNA discovery using small RNA sequencing in post-mortem human
721 brain. BMC Genomics 17:776.
- 722 54. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL,
723 Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. 2005. MicroRNA
724 expression profiles classify human cancers. Nature 435:834-8.
- 725 55. Kim HK, Kim J, Korolevich S, Choi IJ, Kim CH, Munroe DJ, Green JE. 2011. Distinctions
726 in gastric cancer gene expression signatures derived from laser capture microdissection
727 versus histologic macrodissection. BMC Med Genomics 4:48.
- 728 56. Klee EW, Erdogan S, Tillmans L, Kosari F, Sun Z, Wigle DA, Yang P, Aubry MC,
729 Vasmatzis G. 2009. Impact of sample acquisition and linear amplification on gene
730 expression profiling of lung adenocarcinoma: laser capture micro-dissection cell-sampling
731 versus bulk tissue-sampling. BMC Med Genomics 2:13.

- 732 57. Geng R, Furness DN, Muraleedharan CK, Zhang J, Dabdoub A, Lin V, Xu S. 2018. The
733 microRNA-183/96/182 Cluster is Essential for Stereociliary Bundle Formation and Function
734 of Cochlear Sensory Hair Cells. *Sci Rep* 8:18022.
- 735 58. Lumayag S, Haldin CE, Corbett NJ, Wahlin KJ, Cowan C, Turturro S, Larsen PE, Kovacs
736 B, Witmer PD, Valle D, Zack DJ, Nicholson DA, Xu S. 2013. Inactivation of the
737 microRNA-183/96/182 cluster results in syndromic retinal degeneration. *Proc Natl Acad Sci*
738 *U S A* 110:E507-16.
- 739 59. Dambal S, Shah M, Mihelich B, Nonn L. 2015. The microRNA-183 cluster: the family that
740 plays together stays together. *Nucleic Acids Res* 43:7173-88.
- 741 60. Ma Y, Liang AJ, Fan Y-P, Huang Y-R, Zhao X-M, Sun Y, Chen X-F. 2016. Dysregulation
742 and functional roles of miR-183-96-182 cluster in cancer cell proliferation, invasion and
743 metastasis. *Oncotarget* 7:42805-42825.
- 744 61. Kundu ST, Byers LA, Peng DH, Roybal JD, Diao L, Wang J, Tong P, Creighton CJ,
745 Gibbons DL. 2016. The miR-200 family and the miR-183~96~182 cluster target Foxf2 to
746 inhibit invasion and metastasis in lung cancers. *Oncogene* 35:173-86.
- 747 62. Li Y, Zhang H, Li Y, Zhao C, Fan Y, Liu J, Li X, Liu H, Chen J. 2018. MiR-182 inhibits the
748 epithelial to mesenchymal transition and metastasis of lung cancer cells by targeting the Met
749 gene. *Mol Carcinog* 57:125-136.
- 750 63. Zhang L, Quan H, Wang S, Li X, Che X. 2015. MiR-183 promotes growth of non-small cell
751 lung cancer cells through FoxO1 inhibition. *Tumour Biol* 36:8121-6.
- 752 64. Stittrich AB, Haftmann C, Sgouroudis E, Kuhl AA, Hegazy AN, Panse I, Riedel R,
753 Flossdorf M, Dong J, Fuhrmann F, Heinz GA, Fang Z, Li N, Bissels U, Hatam F, Jahn A,
754 Hammoud B, Matz M, Schulze FM, Baumgrass R, Bosio A, Mollenkopf HJ, Grun J, Thiel

- 755 A, Chen W, Hofer T, Loddenkemper C, Lohning M, Chang HD, Rajewsky N, Radbruch A,
756 Mashreghi MF. 2010. The microRNA miR-182 is induced by IL-2 and promotes clonal
757 expansion of activated helper T lymphocytes. *Nat Immunol* 11:1057-62.
- 758 65. Donatelli SS, Zhou JM, Gilvary DL, Eksioglu EA, Chen X, Cress WD, Haura EB, Schabath
759 MB, Coppola D, Wei S, Djeu JY. 2014. TGF-beta-inducible microRNA-183 silences tumor-
760 associated natural killer cells. *Proc Natl Acad Sci U S A* 111:4203-8.
- 761 66. Singaravelu R, Ahmed N, Quan C, Srinivasan P, Ablenas CJ, Roy DG, Pezacki JP. 2019. A
762 conserved miRNA-183 cluster regulates the innate antiviral response. *J Biol Chem*
763 294:19785-19794.
- 764 67. Liu SL, Lerman MI, Miller AD. 2003. Putative phosphatidylinositol 3-kinase (PI3K)
765 binding motifs in ovine betaretrovirus Env proteins are not essential for rodent fibroblast
766 transformation and PI3K/Akt activation. *J Virol* 77:7924-35.
- 767 68. Palmarini M, Maeda N, Murgia C, De-Fraja C, Hofacre A, Fan H. 2001. A
768 phosphatidylinositol 3-kinase docking site in the cytoplasmic tail of the Jaagsiekte sheep
769 retrovirus transmembrane protein is essential for envelope-induced transformation of NIH
770 3T3 cells. *J Virol* 75:11002-9.
- 771 69. Yu S, Lu Z, Liu C, Meng Y, Ma Y, Zhao W, Liu J, Yu J, Chen J. 2010. miRNA-96
772 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. *Cancer*
773 *Res* 70:6015-25.
- 774 70. Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K, Yang GH. 2010. MicroRNA-21 (miR-21)
775 represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung
776 cancer (NSCLC). *Clinica Chimica Acta* 411:846-852.

- 777 71. Cai J, Fang L, Huang Y, Li R, Yuan J, Yang Y, Zhu X, Chen B, Wu J, Li M. 2013. miR-205
778 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in
779 non-small cell lung cancer. *Cancer Res* 73:5402-15.
- 780 72. Wu H, Mo YY. 2009. Targeting miR-205 in breast cancer. *Expert Opinion on Therapeutic*
781 *Targets* 13:1439-1448.
- 782 73. Li C, Yin Y, Liu X, Xi X, Xue W, Qu Y. 2017. Non-small cell lung cancer associated
783 microRNA expression signature: integrated bioinformatics analysis, validation and clinical
784 significance. *Oncotarget* 8:24564-24578.
- 785 74. Edmonds MD, Boyd KL, Moyo T, Mitra R, Duszynski R, Arrate MP, Chen X, Zhao Z,
786 Blackwell TS, Andl T, Eischen CM. 2016. MicroRNA-31 initiates lung tumorigenesis and
787 promotes mutant KRAS-driven lung cancer. *J Clin Invest* 126:349-364.
- 788 75. Lin CW, Chang YL, Chang YC, Lin JC, Chen CC, Pan SH, Wu CT, Chen HY, Yang SC,
789 Hong TM, Yang PC. 2013. MicroRNA-135b promotes lung cancer metastasis by regulating
790 multiple targets in the Hippo pathway and LZTS1. *Nat Commun* 4:1877.
- 791 76. Yeung B, Yu J, Yang X. 2016. Roles of the Hippo pathway in lung development and
792 tumorigenesis. *Int J Cancer* 138:533-9.
- 793 77. Friedman RC, Farh KK, Burge CB, Bartel DP. 2009. Most mammalian mRNAs are
794 conserved targets of microRNAs. *Genome Res* 19:92-105.
- 795 78. Naeem A, Zhong K, Moisés SJ, Drackley JK, Moyes KM, Loor JJ. 2012. Bioinformatics
796 analysis of microRNA and putative target genes in bovine mammary tissue infected with
797 *Streptococcus uberis*. *J Dairy Sci* 95:6397-408.
- 798 79. Xu J, Zhang R, Shen Y, Liu G, Lu X, Wu CI. 2013. The evolution of evolvability in
799 microRNA target sites in vertebrates. *Genome Res* 23:1810-6.

- 800 80. Oliveira GB, Regitano LCA, Cesar ASM, Reecy JM, Degaki KY, Poleti MD, Felício AM,
801 Koltés JE, Coutinho LL. 2018. Integrative analysis of microRNAs and mRNAs revealed
802 regulation of composition and metabolism in Nelore cattle. *BMC Genomics* 19:126.
- 803 81. Ouellet DL, Plante I, Landry P, Barat C, Janelle ME, Flamand L, Tremblay MJ, Provost P.
804 2008. Identification of functional microRNAs released through asymmetrical processing of
805 HIV-1 TAR element. *Nuc Acids Res* 36:2353-65.
- 806 82. Whisnant AW, Kehl T, Bao Q, Materniak M, Kuzmak J, Lochelt M, Cullen BR. 2014.
807 Identification of novel, highly expressed retroviral microRNAs in cells infected by bovine
808 foamy virus. *J Virol* 88:4679-86.
- 809 83. Wang B, Ye N, Cao SJ, Wen XT, Huang Y, Yan QG. 2016. Identification of novel and
810 differentially expressed MicroRNAs in goat enzootic nasal adenocarcinoma. *BMC*
811 *Genomics* 17:896.
- 812 84. Schorn AJ, Gutbrod MJ, LeBlanc C, Martienssen R. 2017. LTR-Retrotransposon Control by
813 tRNA-Derived Small RNAs. *Cell* 170:61-71 e11.
- 814 85. Martin M. 2011. Cutadapt removes adapter sequences from high-throughput sequencing
815 reads. *EMBnetjournal* 17:10-12.
- 816 86. Anders S, Huber W. 2010. Differential expression analysis for sequence count data. *Genome*
817 *Biology* 11:R106.
- 818 87. Spornraft M, Kirchner B, Haase B, Benes V, Pfaffl MW, Riedmaier I. 2014. Optimization of
819 extraction of circulating RNAs from plasma—enabling small RNA sequencing. *PLoS One*
820 9:e107259.
- 821 88. Motameny S, Wolters S, Nürnberg P, Schumacher B. 2010. Next generation sequencing of
822 miRNAs—strategies, resources and methods. *Genes* 1:70-84.

- 823 89. Taxis TM, Bauermann FV, Ridpath JF, Casas E. 2017. Circulating microRNAs in serum
824 from cattle challenged with bovine viral diarrhoea virus. *Frontiers in Genetics* 8:91.
- 825 90. Koh W, Sheng CT, Tan B, Lee QY, Kuznetsov V, Kiang LS, Tanavde V. 2010. Analysis of
826 deep sequencing microRNA expression profile from human embryonic stem cells derived
827 mesenchymal stem cells reveals possible role of let-7 microRNA family in downstream
828 targeting of hepatic nuclear factor 4 alpha. *BMC Genomics* 11:S6.
- 829 91. Clark EL, Bush SJ, McCulloch MEB, Farquhar IL, Young R, Lefevre L, Pridans C, Tsang
830 HG, Wu C, Afrasiabi C, Watson M, Whitelaw CB, Freeman TC, Summers KM, Archibald
831 AL, Hume DA. 2017. A high resolution atlas of gene expression in the domestic sheep (*Ovis*
832 *aries*). *PLoS Genet* 13:e1006997.
- 833 92. McClure LV, Lin YT, Sullivan CS. 2011. Detection of viral microRNAs by Northern blot
834 analysis. *Methods Mol Biol* 721:153-71.
- 835 93. Kramer A, Green J, Pollard J, Jr., Tugendreich S. 2014. Causal analysis approaches in
836 Ingenuity Pathway Analysis. *Bioinformatics* 30:523-30.
- 837 94. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time
838 quantitative PCR and the $2^{-\Delta\Delta C(T)}$ Method. *Methods* 25:402-8.
- 839

840 **FIGURE LEGENDS**

841

842 **Figure 1. Statistics of small RNA sequencing.**

843 A, Read length distribution after quality trimming. The area with highest read abundance
844 corresponds to RNAs with typical miRNA length (21 - 23 nt). B, Percentage of reads in each
845 sample mapping to various RNA categories: snRNA, small nuclear RNA; Mt_rRNA,
846 mitochondrial ribosomal RNA; snoRNA, small nucleolar RNA, Mt_tRNA, mitochondrial
847 transfer RNA; rRNA, ribosomal RNA; misc_RNA, miscellaneous RNA; lincRNA, long
848 intergenic non-coding RNA; JSRV, exogenous JSRV viral genome; DNA, sheep genome;
849 Unmapped, reads not mapping to any of the previous categories. No statistically significant
850 differences were observed between groups (t-test $p < 0.05$).

851

852 **Figure 2. Differential expression of miRNAs in JSRV-infected compared to mock-**
853 **inoculated lambs.**

854 A, Principal component analysis of miRNA expression in lung tissue (JSRV-infected lambs
855 (n=4), mock-inoculated lambs (n=4)). Greater distance between samples in the plot indicates
856 distinct expression patterns. Mock-inoculated samples formed a cluster towards the left of the
857 plot, JSRV-infected samples covered a larger distance in both the x (PC1) and y axes (PC2).
858 Sample Infected_F_85_days of the JSRV-infected group was closest to the mock-infected group
859 in both PC1 and PC2, reflecting the lower level of infection in this lamb (33). The PCA plot
860 indicates greater variability between JSRV-infected samples than among the mock-infected
861 group and suggests global expression differences between the two groups. B, Heatmap of
862 differentially expressed miRNAs ($FDR < 0.05$, $\log_2(\text{fold change}) \geq 0.58$ or ≤ -0.42) between lung

863 tissue of JSRV-infected and mock-inoculated lambs. Dendrogram shows correlation clustering of
864 individuals in groups. Legend represents values of log₂ fold change.

865

866 **Figure 3. RT-qPCR analysis of miRNA expression in lung tissue of JSRV-infected and**
867 **uninfected sheep.**

868 The expression of selected miRNAs was measured by RT-qPCR in lung tissue from JSRV-
869 infected lambs (n=4) and mock-inoculated controls (n=4) (A, B), and in adult sheep with
870 naturally acquired OPA (n=10) and clinically healthy control sheep (n=6) (C, D). A and C,
871 Relative miRNA expression presented as -dCt (-Ct miR + Ct miR-191) of each individual
872 sample per each miRNA assayed. Boxes display standard deviations of the mean, represented
873 with a horizontal line. B and D, log₂ fold-change between groups for each assayed miRNA,
874 calculated following the ddCt method (94) and using miR-191 as an endogenous control. Error
875 bars indicate standard deviation of miRNA expression within groups.

876

877 **Figure 4. Small RNA-sequencing reads from JSRV-infected and uninfected lung tissue**
878 **aligning to the JSRV genome sequence.**

879 The location of reads mapping to the JSRV genome in JSRV-infected (upper 4 panels) and
880 mock-inoculated (lower 4 panels) sheep are shown. The orange arrow indicates the region
881 around nucleotide 6396-6450 where a peak of reads was observed in JSRV-infected animals (see
882 main text and Figure 5). The blue arrow indicates the mapping location of the tRNA^{Lys}¹⁻² 3'-tRF
883 molecule.

884

885

886 **Figure 5. Evaluation of a potential miRNA encoded in the *env* region of the JSRV genome.**

887 A, Secondary structure prediction of the region of the JSRV₂₁ genome (nucleotides 6396 – 6451)
888 that encompasses the putative small RNA detected by small RNA sequencing. Colour legend
889 shows the base-pair probabilities. The prediction was created with RNAfold (48). B, Northern
890 blot analysis to detect the candidate JSRV miRNA. RNA from ovine lung tissue and transfected
891 293T cells was hybridized with probes for 5p and 3p arms of the putative JSRV miRNA and for
892 cellular miR-191, as indicated. Samples 172 and 173 are control lung tissue from healthy sheep;
893 samples JA875, JA876 and JA898 are OPA-affected lung tissue (from 3 independent field
894 cases); pCMV2JS₂₁ transfected 293T cells, pJSRV₂₁ transfected 293T cells, pEGFP-Flag control
895 transfected 293T cells. Upper panels show 24 hours exposure, lower panels show 4 day
896 exposure. miR-191 was used as endogenous positive control.

897

898 **Figure 6. Diseases and Biofunctions associated with differentially expressed predicted**
899 **target genes.**

900 The differentially expressed miRNAs were analyzed with Ingenuity Pathway Analysis software
901 to identify potential target genes in the previously published dataset of genes differentially
902 expressed in OPA (33). The figure shows the diseases and biofunctions associated with genes
903 predicted to be targeted by miRNAs differentially expressed in JSRV-infected sheep lung,
904 plotted by relative statistical significance. Significance values were calculated based on a right-
905 tailed Fisher's exact test, and the $\log(P$ value) is displayed on the horizontal axis of the bar chart.
906 The taller the bar, the more significant the pathway effect.

907

908

909
910

911 **Table 1. Read mapping statistics.**

912

913

Lamb ^a	Total No. of reads	No. of reads post quality trimming (%)	% total reads mapping to miRBase	% total reads mapping to JSRV genome
Infected_M_66days	23042889	18542545 (87.0)	68.77	0.0022
Infected_F_85days	19063580	15645204 (88.9)	72.68	0.0012
Infected_M_71days	29347531	23478540 (88.4)	64.66	0.0028
Infected_M_85days	23400784	19495005 (93.2)	64.86	0.0016
Control_M_66days	20380787	16831901(88.3)	69.18	0.0011
Control_M_85days	23674153	19258905 (90.6)	68.43	0.0008
Control_M_71days	25491448	20009358 (88.1)	69.58	0.0010
Control_F_85days	23304071	20497050 (92.0)	79.10	0.0008

914

915 ^a The lamb identifiers indicate the infection status, sex (male [M] or female [F]) and number of
916 days post-inoculation when culled.

917

918

919

920

921

922 **Table 2. Differentially expressed miRNAs in JSRV-infected and mock-inoculated lung**
 923 **tissue.**

miRNA	Average counts ¹	log ₂ (fold change) ²	FDR ³
miR-182 ⁴	20880.16	3.20	0
miR-183 ⁴	7512.52	3.03	4.28E-84
miR-96 ⁴	343.43	3.15	5.94E-69
miR-135b ⁴	70.94	4.82	1.28E-61
miR-205 ⁴	4802.59	1.29	1.01E-14
miR-132	118.12	1.40	2.09E-11
miR-450b	4841.10	1.04	1.25E-08
miR-424-3p	188.42	1.07	4.56E-07
miR-193b	1564.57	0.92	5.68E-07
miR-130b-5p	130.98	1.13	7.09E-07
miR-215	105.36	1.08	1.66E-06
miR-31 ⁴	252.35	0.91	2.06E-05
miR-424-5p	1250.31	0.87	2.15E-05
miR-21-5p ⁴	28385.89	0.75	5.08E-05
miR-1247-5p	161.02	0.75	1.53E-04
miR-450a	1564.13	0.79	1.66E-04
miR-203b-5p	146.58	0.86	4.95E-04
miR-3601	141.28	0.82	6.74E-04
miR-210	547.69	0.70	8.33E-04
miR-146b	29159.79	0.61	8.61E-04
miR-21-3p	1407.30	0.69	1.22E-03
miR-153	94.21	0.74	2.95E-03
miR-130b	690.02	0.70	2.98E-03
miR-203a-3p	963.90	0.61	6.78E-03
miR-146b-3p	58.90	0.72	1.08E-02
miR-4286	90.54	0.61	4.02E-02
miR-143	3626500.56	-0.57	0
miR-592	119.44	-0.95	4.83E-05
miR-30c-1-3p	275.96	-0.53	3.06E-02
miR-874-3p	514.64	-0.57	3.13E-02
let-7i-3p	441.42	-0.51	3.72E-02
miR-4634	395.30	-0.56	3.80E-02

924 ¹Mean normalized counts across all 8 samples. ²Threshold established at log₂(fold change) ≤ -0.42. ³FDR

925 corrected by Benjamini-Hochberg, threshold FDR ≤ 0.05. ⁴miRNAs also validated by RT-qPCR.




Figure 1. Statistics of small RNA sequencing.

A. Read length distribution after quality trimming. The area with highest read abundance corresponds to RNAs with typical miRNA length (21 - 23 nt).

B. Percentage of reads in each sample mapping to various RNA categories: snRNA, small nuclear RNA; Mt_rRNA, mitochondrial ribosomal RNA; snoRNA, small nucleolar RNA; Mt_tRNA, mitochondrial transfer RNA; rRNA, ribosomal RNA; misc_RNA, miscellaneous RNA; lincRNA, long intergenic non-coding RNA; JSRV, exogenous JSRV viral genome; DNA, sheep genome; Unmapped, reads not mapping to any of the previous categories. No statistically significant differences were observed between groups (t-test $p < 0.05$).




Figure 2. Differential expression of miRNAs in JSRV-infected compared to mock-inoculated lambs.

A. Principal component analysis of miRNA expression in lung tissue (JSRV-infected lambs (n=4), mock-inoculated lambs (n=4)). Greater distance between samples in the plot indicates distinct expression patterns. Mock-inoculated samples formed a cluster towards the left of the plot, JSRV-infected samples covered a larger distance in both the x (PC1) and y axes (PC2). Sample Infected_F_85_days of the JSRV-infected group was closest to the mock-infected group in both PC1 and PC2, reflecting the lower level of infection in this lamb (33). The PCA plot indicates greater variability between JSRV-infected samples than among the mock-infected group and suggests global expression differences between the two groups. B. Heatmap of differentially expressed miRNAs (FDR<0.05, $\log_2(\text{fold change}) \geq 0.58$ or ≤ -0.42) between lung tissue of JSRV-infected and mock-inoculated lambs. Dendrogram shows correlation clustering of individuals in groups. Legend represents values of \log_2 fold change.




Figure 3. RT-qPCR analysis of miRNA expression in lung tissue of JSRV-infected and uninfected sheep.

The expression of selected miRNAs was measured by RT-qPCR in lung tissue from JSRV-infected lambs (n=4) and mock-inoculated controls (n=4) (A, B), and in adult sheep with naturally acquired OPA (n=10) and clinically healthy control sheep (n=6) (C, D). A and C, Relative miRNA expression presented as -dCt (-Ct miR + Ct miR-191) of each individual sample per each miRNA assayed. Boxes display standard deviation of the mean, represented with a horizontal line. B and D, log₂ fold-change between groups for each assayed miRNA, calculated following the ddCt method (94) and using miR-191 as an endogenous control. Error bars indicate standard deviation of miRNA expression within groups.




Figure 4. Small RNA-sequencing reads from JSRV-infected and uninfected lung tissue aligning to the JSRV genome sequence.

The location of reads mapping to the JSRV genome in JSRV-infected (upper 4 panels) and mock-inoculated (lower 4 panels) sheep are shown. The orange arrow indicates the region around nucleotide 6396-6450 where a peak of reads was observed in JSRV-infected animals (see main text and Figure 5). The blue arrow indicates the mapping location of the tRNA^{Lys}^{1,2} 3'-tRF molecule.




Figure 5. Evaluation of a potential miRNA encoded in the *env* region of the JSRV genome.

A. Secondary structure prediction of the region of the JSRV₂₁ genome (nucleotides 6396 – 6451) that encompasses the putative small RNA detected by small RNA sequencing. Colour legend shows the base-pair probabilities. The prediction was created with RNAfold (48). B. Northern blot analysis to detect the candidate JSRV miRNA. RNA from ovine lung tissue and transfected 293T cells was hybridized with probes for 5p and 3p arms of the putative JSRV miRNA and for cellular miR-191, as indicated. Samples 172 and 173 are control lung tissue from healthy sheep; samples JA875, JA876 and JA898 are OPA-affected lung tissue (from 3 independent field cases); pCMV2JS₂₁ transfected 293T cells, pJSRV₂₁ transfected 293T cells, pEGFP-Flag control transfected 293T cells. Upper panels show 24 hours exposure, lower panels show 4 day exposure. miR-191 was used as endogenous positive control.




Figure 6. Diseases and Biofunctions associated with differentially expressed predicted target genes.

The differentially expressed miRNAs were analyzed with Ingenuity Pathway Analysis software to identify potential target genes in the previously published dataset of genes differentially expressed in OPA (33). The figure shows the diseases and biofunctions associated with genes predicted to be targeted by miRNAs differentially expressed in JSRV-infected sheep lung, plotted by relative statistical significance. Significance values were calculated based on a right-tailed Fisher's exact test, and the $\log(P$ value) is displayed on the horizontal axis of the bar chart. The taller the bar, the more significant the pathway effect.